Carras S, Torroja A, Emadali A, Montaut E, et al. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group. Haematologica 2023 Nov 30. doi: 10.3324/haematol.2023.283724.
PMID: 38031755